en
Pharmaceuticals
Over the past decade, Novartis Pharmaceuticals Canada has introduced 20 new medicines that have had an important impact on patients suffering from a wide variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation and osteoporosis.
A C D E F G I L M N P R S T V X Z
Enablex*
(darifenacin)
Muscarinic M3 Selective Receptor Antagonist
*Enablex is a registered trademark
Estalis*
(norethindrone acetate and estradiol-17ß)
Progestin-Estrogen
*Estalis is a registered trademark
Estraderm*
(estradiol-17ß)
Estrogen
*Estraderm is a registered trademark
Estradot*
(estradiol-17ß)
Estrogen
*Estradot is a registered trademark
Exelon*
(rivastigmine hydrogen tartrate)
Cholinesterase Inhibitor
Important information for healthcare professionals (2001)
*Exelon is a registered trademark
Exelon* Patch
(rivastigmine transdermal patch)
Cholinesterase Inhibitor
Important information for healthcare professionals (2010)
*Exelon is a registered trademark
Exjade*
(deferasirox)
Iron Chelating Agent
Important information for healthcare professionals (2009)
Important information for healthcare professionals (2008)
Important information for healthcare professionals (2007)
*Exjade is a registered trademark
Extavia*
(Interferon beta-1b)
Immunomodulator
*Extavia is a registered trademark
Research
Novartis is one of the industry’s biggest investors in research.
ABOUT NOVARTIS
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis
Sandoz
Sandoz is one of the leaders in the development, manufacturing and distribution of generic pharmaceutical products.